Physician profile
Thomas Grahm
NPI 1568465474
$2,265.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $185 · 2021: $563 · 2022: $347 · 2023: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.01 | 2023 | Andexxa |
| Ethicon US, LLC | $396.03 | 2020-2023 | Echelon Flex, Ethicon |
| Alphatec Spine, INC | $298.57 | 2019 | |
| Medtronic, INC. | $261.49 | 2021-2023 | Activa PC |
| Gt Medical Technologies, INC | $174.04 | 2022 | |
| Acera Surgical, INC. | $134.14 | 2023 | Restrata Wound Matrix |
| Pacira Pharmaceuticals Incorporated | $111.50 | 2021 | |
| Medtronic USA, INC. | $92.29 | 2019 | |
| Stryker Corporation | $88.78 | 2021 | |
| Tela Bio, INC. | $87.77 | 2022 | |
| Kci USA, INC. | $78.15 | 2020 | |
| Intrinsic Therapeutics | $61.51 | 2020 | |
| Integra Lifesciences Corporation | $25.99 | 2021 | |
| Abbott Laboratories | $23.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Grahm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.